Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

CG Oncology (CGON) EBIT Margin: 2023-2025

Historic EBIT Margin for CG Oncology (CGON) over the last 2 years, with Sep 2025 value amounting to -3,068.97%.

  • CG Oncology's EBIT Margin rose 6273336.00% to -3,068.97% in Q3 2025 from the same period last year, while for Sep 2025 it was -8,124.63%, marking a year-over-year increase of 590637.00%. This contributed to the annual value of -10,067.25% for FY2024, which is 1711363.00% up from last year.
  • As of Q3 2025, CG Oncology's EBIT Margin stood at -3,068.97%, which was up 96.22% from -81,161.54% recorded in Q1 2025.
  • CG Oncology's EBIT Margin's 5-year high stood at -3,068.97% during Q3 2025, with a 5-year trough of -1,935,500.00% in Q4 2023.
  • Its 3-year average for EBIT Margin is -253,606.61%, with a median of -23,290.99% in 2024.
  • As far as peak fluctuations go, CG Oncology's EBIT Margin skyrocketed by 192,715,592bps in 2024, and later tumbled by 7,691,409bps in 2025.
  • Over the past 3 years, CG Oncology's EBIT Margin (Quarterly) stood at -1,935,500.00% in 2023, then skyrocketed by 192,715,592bps to -8,344.08% in 2024, then spiked by 6,273,336bps to -3,068.97% in 2025.
  • Its last three reported values are -3,068.97% in Q3 2025, -81,161.54% for Q1 2025, and -8,344.08% during Q4 2024.